Minerva Neurosciences | NERV - Ebit

Stock Price
6.33
Daily Change
0.02 0.32%
Monthly
46.53%
Yearly
222.96%
Q1 Forecast
2.46

Minerva Neurosciences reported $-4.37M in EBIT for its fiscal quarter ending in September of 2024.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Adma Biologics USD 49.19M 7.26M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
AstraZeneca USD 2.97B 4.48B Dec/2025
BioCryst Pharmaceuticals USD -4.51M 12.2M Dec/2024
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -5.44M 3.76M Dec/2022
Compugen USD -7.89M 536K Sep/2025
CSL USD 2.75B 1.35B Dec/2024
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Esperion Therapeutics USD -16.03M 11.51M Sep/2024
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
J&J USD 5.11B 2.3B Dec/2025
Merck USD 6.24B 1.32B Dec/2025
Minerva Neurosciences USD -4.37M 1.71M Sep/2024
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Novavax USD -134.02M 49.55M Sep/2024
Pfizer USD 4.65B 71M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Takeda JPY 257.49B 568.56B Dec/2025
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024